Actively Recruiting
Phase 2 Study of a 5-Strain Probiotic to Prevent Bone Loss in Women with Early-Stage Hormone Receptor-Positive Breast Cancer Starting Aromatase Inhibitor Therapy
Led by Mayo Clinic · Updated on 2026-08-10
38
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a probiotic called WBF-038 in patients with early-stage hormone receptor-positive breast cancer who are beginning treatment with aromatase inhibitors. Aromatase inhibitors reduce estrogen production to help prevent cancer growth but can negatively impact bone health, weight, blood sugar, and waist size. This Phase II trial aims to see if WBF-038 can help prevent bone loss and improve metabolic health during this treatment. Participants receive WBF-038 by mouth once daily for 365 days, starting three months after beginning aromatase inhibitor therapy, unless disease progression or unacceptable side effects occur. During the study, patients undergo blood sample collections and bone mineral density tests at screening and various points throughout the trial. After completing the year of probiotic treatment, participants are followed up for 90 days. Throughout the study, researchers measure changes in bone turnover markers, bone mineral density in the lumbar spine and hips, blood sugar levels, weight, waist circumference, and inflammatory markers. Patient-reported symptoms related to aromatase inhibitor treatment are also assessed. Safety and fracture risk are monitored by tracking adverse events. The total participation is approximately 18 months from baseline to final follow-up.
CONDITIONS
Brief Title
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
Research Team
C
Clinical Trials Referral Office
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here